Fundz

Alzheon

Framingham, Massachusetts, United States · Biotechnology

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and

Key facts

Headquarters
Framingham, Massachusetts, United States
Employees
31
Industries
Biotechnology
Status
Private
Website
alzheon.com
LinkedIn
Company page

Recent activity at Alzheon

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Alzheon funding history

DateRoundAmount
Aug 2026Venture$78.8M
Jun 2024Series E$100.0M
Feb 2024Venture$17.2M
Dec 2022Series D$1.7M
Apr 2022Series D$50.0M

Leadership

  • Martin Tolar, Director, Executive Officer
  • Diane M.D., Director
  • Noel Dunn, Director
  • David Ph.D., Director
  • Jordan Heller, Director
  • Neil Flanzraich, Director
  • Martin Ph.D., Director, Executive Officer
  • Jean-Pierre Garnier, Director
  • Dennis Langer, Director
  • Franz Hefti, Director

Verified email and direct lines for Alzheon’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Alzheon files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Alzheon in the news

Companies similar to Alzheon

About Alzheon: questions and answers

What does Alzheon do?

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and

Where is Alzheon headquartered?

Alzheon is headquartered in Framingham, Massachusetts, United States.

How many employees does Alzheon have?

Alzheon has about 31 employees.

Has Alzheon raised funding?

Yes. Fundz has recorded 5 funding events for Alzheon. The most recent, $78.8M, was in Aug 2026.

What is the latest news on Alzheon?

On Aug 26, 2026, ALZHEON

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Alzheon across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.